報價延遲最少15分鐘:2024/12/23 22:15 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.15 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.32/-0.42
|
|
企業價值
191.76M
|
| 資產負債 |
|
每股賬面淨值
0.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |